Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels. It is often used for patients with angina who remain symptomatic despite optimal treatment with other antianginal drugs . Nicorandil is a dual-action potassium channel opener that relaxes vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and increased intracellular concentration of cyclic GMP. It is shown to dilate normal and stenotic coronary arteries and reduces both ventricular preload and afterload .
Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes.
Pusan National University Hospital, Pusan, Korea, Republic of
Xuzhou Central Hospital, Xuzhou, Jiangsu, China
Chinese PLA General Hospital, Beijing, Beijing, China
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
National Institute of Cardiovascular Diseases, Karachi, Sind, Pakistan
For Locations in, Beijing, China
Toujinkai Hospital, Kyoto, Japan
Aarhus Hospital, Aarhus, Denmark
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.